Aengevaeren W R, Uijen G J, Jukema J W, Bruschke A V, van der Werf T
Department of Cardiology, University Hospital Nijmegen, the Netherlands.
Circulation. 1997 Jul 15;96(2):429-35. doi: 10.1161/01.cir.96.2.429.
Lipid-lowering therapy during 2 years in the Regression Growth Evaluation Statin Study (REGRESS) was associated with less progression of coronary atherosclerosis in the pravastatin group compared with the placebo group. The effect of lipid-lowering therapy on the functional state of the coronary circulation is less well known. The purpose of this study was to evaluate this effect.
In a substudy of REGRESS, 69 patients were randomized to pravastatin or placebo. Thirty-seven of these patients were allocated to the medical management stratum. Quantitative coronary angiography, regional myocardial perfusion, exercise testing, and classification of angina pectoris were assessed at baseline and after 2 years of therapy. Regional myocardial perfusion was assessed by digital subtraction angiography after intracoronary papaverine with video-densitometric calculation of the hyperemic mean transit time (HMTT) of contrast. In the medical management stratum, regional myocardial perfusion was assessed in 31 regions in the pravastatin group and 25 regions in the placebo group. The change in HMTT in the pravastatin group was -0.18 seconds (-5%) and in the placebo group +0.52 seconds (+18%), a difference of 0.70 seconds (P=.004). The mean difference in change in classification of angina pectoris (scale, 1 to 4) between pravastatin and placebo was 0.7 (P=.03) in favor of the pravastatin-treated patients. The change in HMTT was correlated with the change in exercise time (r=-.65, P=.002).
In patients with symptomatic coronary artery disease, treatment with the HMG-coenzyme A reductase inhibitor pravastatin during 2 years resulted in a preserved regional myocardial perfusion, whereas patients on placebo deteriorated. The classification of angina pectoris improved only in patients receiving pravastatin. In lipid-lowering therapy, the evaluation of myocardial perfusion by assessment of the HMTT reveals a combined measure of functional and structural changes in the coronary circulation.
在回归生长评估他汀类药物研究(REGRESS)中,与安慰剂组相比,普伐他汀组进行两年的降脂治疗与冠状动脉粥样硬化进展减缓相关。降脂治疗对冠状动脉循环功能状态的影响尚鲜为人知。本研究的目的是评估这种影响。
在REGRESS的一项子研究中,69例患者被随机分为普伐他汀组或安慰剂组。其中37例患者被分配到药物治疗层。在基线和治疗2年后评估定量冠状动脉造影、局部心肌灌注、运动试验和心绞痛分级。冠状动脉内注射罂粟碱后,通过数字减法血管造影评估局部心肌灌注,并通过视频密度测定法计算造影剂的充血平均通过时间(HMTT)。在药物治疗层,普伐他汀组评估了31个区域的局部心肌灌注,安慰剂组评估了25个区域。普伐他汀组HMTT的变化为-0.18秒(-5%),安慰剂组为+0.52秒(+18%),差异为0.70秒(P = 0.004)。普伐他汀组和安慰剂组之间心绞痛分级变化(范围为1至4级)的平均差异为0.7(P = 0.03),有利于接受普伐他汀治疗的患者。HMTT的变化与运动时间的变化相关(r = -0.65,P = 0.002)。
在有症状的冠状动脉疾病患者中,使用HMG辅酶A还原酶抑制剂普伐他汀进行两年治疗可使局部心肌灌注得以保留,而服用安慰剂的患者则出现恶化。仅接受普伐他汀治疗的患者心绞痛分级得到改善。在降脂治疗中,通过评估HMTT来评估心肌灌注揭示了冠状动脉循环中功能和结构变化的综合指标。